Wednesday 27 March 2013

Bee Venom Can Kill HIV, Study Says






Scientists from Washington University School of Medicine in St. Louis have discovered bee venom can kill the HIV virus without harming the body.
Bees could hold the key to preventing HIV transmission. Researchers have discovered that bee venom kills the virus while leaving body cells unharmed, which could lead to an anti-HIV vaginal gel and other treatments.
Scientists at the Washington University School of Medicine in St. Louis found that melittin, a toxin found in bee venom, physically destroys the HIV virus, a breakthrough that could potentially lead to drugs that are immune to HIV resistance. The study was published Thursday in the journal Antiviral Therapy.
“Our hope is that in places where HIV is running rampant, people could use this as a preventative measure to stop the initial infection,” Joshua Hood, one of the authors of the study, said in a statement.
The researchers attached melittin to nanoparticles that are physically smaller than HIV, which is smaller than body cells. The toxin rips holes in the virus’ outer layer, destroying it, but the particles aren’t large enough to damage body cells.
“Based on this finding, we propose that melittin-loaded nanoparticles are well-suited for use as topical vaginal HIV virucidal agents,” they write.
Theoretically, the particles could also be injected into an HIV-positive person to eliminate the virus in the bloodstream.
Because the toxin attacks the virus’ outer layer, the virus is likely unable to develop a resistance to the substance, which could make it more effective than other HIV drugs.
“Theoretically, melittin nanoparticles are not susceptible to HIV mutational resistance seen with standard HIV therapies,” they write. “By disintegrating the [virus'] lipid envelope [it's] less likely to develop resistance to the melittin nanoparticles.”
The group plans to soon test the gel in clinical trials.

HAPPY HOLI



వివిధ వర్ణాల పొడులను, నీళ్ళను చల్లుకొనే ఉత్సవ౦ ఈ రోజున ఆచరి౦చాలని ధర్మశాస్త్ర౦ చెబుతో౦ది. ఇదే వస౦తోత్సవ౦. ’వస౦తాలు ఆడడ౦’ అనే ఆచార౦గా తెలుగునాడు ప్రాచీనకాల౦ ను౦డి ప్రాచుర్య౦ పొ౦ది౦ది ఈ ప౦డుగ.

ఈ రోజున ఉదయాన్నే ’తైలాభ్య౦గనము’ చేయాలి(తలకు నూనె రాసుకొని, ఒ౦టికి నలుగు పెట్టుకొని స్నాన౦ చేయాలి). తరువాత ’చూత కుసుమ భక్షణ౦’ అనే ప్రక్రియను ఆచరి౦చాలి.

దాని విధి: ఆవు పేడతో అలికిన ఇ౦టి ప్రా౦గణ౦లో తెల్లని వస్త్రాన్ని ఆసన౦గా చేసుకొని, తూర్పు ముఖ౦గా కూర్చుని, ఒక ముత్తైదువచే వ౦దన తిలక౦, నీరాజన౦ పొ౦ది చ౦దన౦తో కూడిన మామిడి పువ్వును భక్షి౦చాలి. ఇది అన్ని కోరికలను తీర్చుతు౦దని శాస్త్రోక్తి.

చూతమగ్ర్య౦ వస౦తస్య మాక౦దకుసుమ౦ తవ!
సచ౦దన౦ పిబామ్యద్య సర్వకామార్థ సిద్ధయే!!

అనే శ్లోక౦తో మామిడి పూతను స్వీకరి౦చాలి.
పౌరులు, జానపదులు అ౦తా కలిసి సి౦ధూర చూర్ణ౦, భర్గు౦డ, చ౦దనపు పొడి వ౦టి వాటిని జల్లుకొని తా౦బూలాలిచ్చుకొని నృత్య గీత వాద్యాలతో మహోత్సవ౦ చేయాలని శాస్త్రాలు చెబుతున్నాయి. ఇదీ ర౦గులు జల్లుకొనే పద్ధతి.


Source: Brahmasri Chaganti Koteswara Rao



Tuesday 26 March 2013

Drug Patent Expirations for the week of March 24, 2013


Drug Patent Expirations for the week of March 24, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
XOPENEX HFASunovionlevalbuterol tartrate5,362,755Mar 25, 2013
XOPENEXSunovionlevalbuterol hydrochloride5,362,755Mar 25, 2013
SILENORSomaxondoxepin hydrochloride5,502,047Mar 26, 2013
LOVAZASmithkline Beechamomega-3-acid ethyl esters5,502,077Mar 26, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

GPAT 2013 SAMPLE ONLINE TEST- AICTE

Tuesday 19 March 2013

Friday 15 March 2013

Dr.Reddy's Laboratories Founder Anji Reddy passes away

 






Dr. K. Anji Reddy, Founder and Chairman of  Dr. Reddy's Laboratories, died at a hospital in Hyderabad on Friday. He was 72. He is survived by his wife Samrajyam, daughter Anuradha and son K. Satish Reddy.
An acknowledged pioneer of reverse engineering, Dr. Reddy was held in high esteem by the scientific community dealing with pharmaceuticals. His contribution was significant in making pharmaceutical products globally competitive and, at the same time, affordable to the common man.
He was known for leveraging genuine technological interventions to make active pharmaceutical ingredients effective.
Apart from his pre-eminent position in the pharmaceutical industry, Dr. Reddy was active in "giving back to society" and established the Dr. Reddy's Foundation and the Naandi Foundation.

Dr. Reddy was ailing for the past few months from a lung disorder and was admitted to a private hospital about 10 days ago where a team of doctors attended on him round-the-clock. The end came around 4.30 p.m. on Friday.



PHARMA CAREER SUMMIT-2013, HYDERABAD





Hyderabad16th March 2013G. Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad 500 028.


Tuesday 12 March 2013

Drug Patent Expirations for the week of March 10, 2013

Drug Patent Expirations for the week of March 10, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
FLO-PREDTaroprednisolone acetate6,102,254Mar 11, 2013
ABRAXANEAbraxis Biosciencepaclitaxel5,498,421Mar 12, 2013
COMBIVENT RESPIMATBoehringer Ingelheimalbuterol sulfate; ipratropium bromide5,497,944Mar 12, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Drug Patent Expirations for the week of March 10, 2013

Drug Patent Expirations for the week of March 10, 2013

TradenameApplicantGeneric NamePatent No.Patent Expiration
FLO-PREDTaroprednisolone acetate6,102,254Mar 11, 2013
ABRAXANEAbraxis Biosciencepaclitaxel5,498,421Mar 12, 2013
COMBIVENT RESPIMATBoehringer Ingelheimalbuterol sulfate; ipratropium bromide5,497,944Mar 12, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

JNTU-HYD : Part Time PG (PTPG) programmes - 2013 Admissions

Saturday 9 March 2013